Vasoactive Agents for Adult Septic Shock: An Update and Review
| Autor: | Jeremy R. DeGrado, Kevin E. Anger, Mark A Dalimonte |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
medicine.medical_specialty business.industry Septic shock 030208 emergency & critical care medicine medicine.disease Shock Septic Sepsis Intensive Care Units Norepinephrine 03 medical and health sciences 0302 clinical medicine Vasoactive agent Vasoactive Humans Vasoconstrictor Agents Medicine Pharmacology (medical) 030212 general & internal medicine business Intensive care medicine |
| Zdroj: | Journal of Pharmacy Practice. 33:523-532 |
| ISSN: | 1531-1937 0897-1900 |
| DOI: | 10.1177/0897190019844124 |
| Popis: | Purpose The objective of this article is to discuss the pharmacology, side effects, and clinical application of vasoactive therapy in the management of adult septic shock. Summary Sepsis is one of the most common reasons for admission to an intensive care unit with the incidence estimated to be greater than 750 000 cases per year in the United States. Clinicians should understand the basic pharmacology of available vasoactive agents to allow for routine and complex management of septic shock. Conclusion While advances in research, identification, and early implementation of best practices for the treatment of sepsis has reduced mortality, rates remain high. Vasopressors and inotropes remain part of the core therapeutic modalities of sepsis management. Norepinephrine is the first-line vasopressor of choice for septic shock, though secondary vasopressors can be used depending on the patient’s circumstances. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|